[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2286442A1 - Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie - Google Patents

Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie Download PDF

Info

Publication number
CA2286442A1
CA2286442A1 CA002286442A CA2286442A CA2286442A1 CA 2286442 A1 CA2286442 A1 CA 2286442A1 CA 002286442 A CA002286442 A CA 002286442A CA 2286442 A CA2286442 A CA 2286442A CA 2286442 A1 CA2286442 A1 CA 2286442A1
Authority
CA
Canada
Prior art keywords
reperfusion
hearts
ischemia
ischaemia
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286442A
Other languages
English (en)
Inventor
Jean-Francois Bouchard
Daniel Lamontagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002286442A priority Critical patent/CA2286442A1/fr
Priority to AU10127/01A priority patent/AU1012701A/en
Priority to PCT/CA2000/001242 priority patent/WO2001028588A1/fr
Publication of CA2286442A1 publication Critical patent/CA2286442A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002286442A 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie Abandoned CA2286442A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002286442A CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie
AU10127/01A AU1012701A (en) 1999-10-15 2000-10-16 Cannabinoids as vasodilators and cardioprotectors against ischemia
PCT/CA2000/001242 WO2001028588A1 (fr) 1999-10-15 2000-10-16 Cannabinoides utilises en tant que vasodilatateurs et cardioprotecteurs contre l'ischemie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002286442A CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie

Publications (1)

Publication Number Publication Date
CA2286442A1 true CA2286442A1 (fr) 2001-04-15

Family

ID=4164389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286442A Abandoned CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie

Country Status (3)

Country Link
AU (1) AU1012701A (fr)
CA (1) CA2286442A1 (fr)
WO (1) WO2001028588A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004052697A1 (de) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
BRPI0719203A2 (pt) * 2006-10-04 2014-02-04 Neurokey As Uso de fármacos indutores de hipotermia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1999026612A1 (fr) * 1997-11-21 1999-06-03 Smithkline Beecham Corporation Nouveaux modulateurs de recepteurs de cannabinoïdes

Also Published As

Publication number Publication date
WO2001028588A1 (fr) 2001-04-26
AU1012701A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
Tissier et al. Pharmacological postconditioning with the phytoestrogen genistein
Bouchard et al. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart
Przyklenk et al. " Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow.
Chen et al. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts
Arikan et al. Lipid-based antifungal agents current status
Pang et al. Pharmacological augmentation of skin flap viability: a hypothesis to mimic the surgical delay phenomenon or a wishful thought
Hori et al. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization.
Vinten-Johansen Postconditioning: a mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion
US6444681B1 (en) Methods and compositions for treating Raynaud's Phenomenon and scleroderma
Iino et al. Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion
Bouchard et al. Role of kinins in the endothelial protective effect of ischaemic preconditioning
Wallace et al. Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester
Chan et al. 3, 4-Dihydroxyflavonol enhances nitric oxide bioavailability and improves vascular function after ischemia and reperfusion injury in the rat
Pratschke et al. Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury
Shahidullah et al. Cyclic GMP, sodium nitroprusside and sodium azide reduce aqueous humour formation in the isolated arterially perfused pig eye
CA2286442A1 (fr) Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie
GB2436255A (en) Organ preconditioning, arrest, protection, preservation and recovery (2)
Yoshimoto et al. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A
Kruuse et al. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig
Nakamura et al. A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium
Atkinson et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function of mesenteric arterial bed of rat
Abran et al. Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs
Kauder et al. Antioxidant properties of dihydropyridines in isolated rat hearts: Comparison of nisoldipine, nisoldipine enantiomers, and nifedipine
Simpson et al. Myocardial ischemia: the potential therapeutic role of prostacyclin and its analogues
Miller et al. CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells

Legal Events

Date Code Title Description
FZDE Dead